Covalon Technologies Announces Conference Call To Discuss Q3 Financial Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV), an advanced medical technologies company, has scheduled a conference call to be held Tuesday August 22, 2017 at 9:00 a.m. EDT, to discuss the third quarter ended June 30, 2017, financial results. The Company intends to release its Q3 financial results on Monday August 21, 2017.

“and statements that an event or result”

The call will be held Tuesday, August 22, 2017 at 9:00 a.m. EDT.

To participate in the live call please dial:

Local / International: 416-640-5946
North American Toll- Free: 1 866-233-4585

A recording of the call will be available on www.covalon.com for replay for 14 days following the live broadcast.

About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon’s patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon’s technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company’s current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan, “estimate”, “expect”, “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company’s ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.